The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L. & Roberts, T. M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315, 239–242 (1985).
White, M. F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 182, 3–11 (1998).
Inukai, K. et al. p85α gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase p50α, p55α, and p85α, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 272, 7873–7882 (1997).
Kaliman, P. et al. Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. Mol. Endocrinol. 12, 66–77(1998).
Ueki, K., Algenstaedt, P., Mauvais-Jarvis, F. & Kahn, C. R. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85 α regulatory subunit. Mol. Cell. Biol. 20, 8035–8046 (2000).
Yu, J. et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18, 1379–1387 (1998).Shows that p85 can both extend the half-life of p110 and inhibit its activity. This inhibitory effect was relieved by the binding of phosphotyrosine peptides to the SH2 domain of p85.
Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527–532 (1994).Links RAS to the PI3K–AKT pathway.
Kodaki, T. et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4, 798–806 (1994).
Cuevas, B. D. et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276, 27455–27461 (2001).
Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356–362 (1997).
Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).References 10 and 11 describe the molecular cloning of PTEN on the basis of breast cancer and glioma studies, respectively, and reports a high frequency of PTEN mutation by various cancer cell lines, xenografts and primary tumours.
Myers, M. P. et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 95, 13513–13518 (1998).
Haas-Kogan, D. et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8, 1195–1198 (1998).
Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998).Shows that PTEN is a negative regulator of AKT and can reduce intracellular levels of PIP 3 and dephosphorylate PIP 3 in vitro.
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 95, 15587–15591 (1998).
Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375–13378 (1998).The first report that PTEN has lipid phosphatase actitivty.
Gu, J. et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146, 389–403 (1999).
Tamura, M. et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280, 1614–1617 (1998).
Scheid, M. P. et al. Phosphatidylinositol(3,4,5)P3 is essential but not sufficient for PKB activation: phosphatidylinositol(3,4)P2 is required for PKB phosphorylation at Ser473. Studies using cells from Ship−/− knockout mice. J. Biol. Chem. 277, 9027 – 9035 (2002).
Helgason, C. D. et al. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of B lymphocytes in SHIP−/− mice. J. Exp. Med. 191, 781–794 (2000).
Liu, Q. et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/AKT activation and myeloid cell survival. Genes Dev. 13, 786–791 (1999).Shows that Ship-deficient mice have hyperproliferation of myeloid cells, increased survival of neutrophils, and enhanced PIP 3 accumulation and Akt activation upon engagement of certain cytokine receptors.
Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905–2927 (1999).
Scheid, M. P. & Woodgett, J. R. PKB/AKT: functional insights from genetic models. Nature Rev. Mol. Cell Biol. 2, 760–768 (2001).
Andjelkovic, M. et al. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272, 31515–31524 (1997).
Bellacosa, A. et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17, 313–325 (1998).
Vanhaesebroeck, B. & Alessi, D. R. The PI3K–PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561–576 (2000).
Stokoe, D. et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277, 567–570 (1997).Shows that PIP 3 is necessary for AKT recruitment to the membrane and phosphorylation of AKT on the PDK1 site (Thr308).
Alessi, D. R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase-Bα. Curr. Biol. 7, 261–269 (1997).
Toker, A. & Newton, A. C. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275, 8271–8274 (2000).
Laine, J., Kunstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene TCL1 is an Akt kinase coactivator. Mol. Cell 6, 395–407 (2000).
Andjelkovic, M. et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC–PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl Acad. Sci. USA 93, 5699–5704 (1996).
Maira, S. M. et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294, 374–380 (2001).
Sato, S., Fujita, N. & Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl Acad. Sci. USA 97, 10832–10837 (2000).
Dudek, H. et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661–665 (1997).
Li, J. et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 58, 5667–5672 (1998).
Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997).Shows that growth-factor-induced activation of AKT phosphorylates BAD and inhibits BAD-induced apoptosis in primary neurons.
Cardone, M. H. et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318–1321 (1998).
Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–868 (1999).
Romashkova, J. A. & Makarov, S. S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86–90 (1999).Shows that PDGF stimulation of fibroblasts causes phosphorylation and activation of IKK by AKT and subsequent activation of NF-κB. This finding links the PI3K–AKT pathway to anti-apoptotic transcription.
Kane, L. P., Shapiro, V. S., Stokoe, D. & Weiss, A. Induction of NF-κB by the Akt/PKB kinase. Curr. Biol. 9, 601–604 (1999).
Mayo, L. D. & Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98, 11598–11603 (2001).Shows that phosphorylation of MDM2 by AKT enhances its nuclear translocation, resulting in destabilization of the p53 protein.
Zhou, B. P. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973–982 (2001).
Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499–3511 (1998).
Graff, J. R. et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275, 24500–24505 (2000).
Dijkers, P. F. et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 20, 9138–9148 (2000).
Medema, R. H., Kops, G. J., Bos, J. L. & Burgering, B. M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–787 (2000).
Lawlor, M. A. & Rotwein, P. Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol. Cell. Biol. 20, 8983–8995 (2000).
Rossig, L. et al. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell. Biol. 21, 5644–5657 (2001).
Vemuri, G. S. & Rittenhouse, S. E. Wortmannin inhibits serum-induced activation of phosphoinositide 3-kinase and proliferation of CHRF-288 cells. Biochem. Biophys. Res. Commun. 202, 1619–1623 (1994).
Castoria, G. et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20, 6050–6059 (2001).Shows that the induction of PI3K triggers oestrogen-dependent S-phase entry in breast cancer cells.
Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R. & Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344, 427–431 (1999).
Brunn, G. J. et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256–5267 (1996).
Bodine, S. C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biol. 3, 1014–1019 (2001).
Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biol. 3, 1009–1013 (2001).
Radimerski, T. et al. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nature Cell Biol. 4, 251–255 (2002).
Liliental, J. et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 10, 401–404 (2000).
Jiang, K. et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nature Immunol. 1, 419–425 (2000).
Welch, H., Eguinoa, A., Stephens, L. R. & Hawkins, P. T. Protein kinase B and Rac are activated in parallel within a phosphatidylinositide 3OH-kinase-controlled signaling pathway. J. Biol. Chem. 273, 11248–11256 (1998).
Han, J. et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279, 558–560 (1998).Shows that phosphorylation of the RAC-specific guanine nucleotide exchange factor (GEF) VAV1 is enhanced by PIP 3 and inhibited by PIP 2 . These findings link a GEF to PI3K-mediated RAC activation.
Welch, H. C. et al. P-Rex1, a PtdIns(3,4,5)P(3)- and Gβγ-regulated guanine-nucleotide exchange factor for Rac. Cell 108, 809–821 (2002).
Krugmann, S. et al. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell 9, 95–108 (2002).
Jimenez, C. et al. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J. Cell Biol. 151, 249–261 (2000).
Brunet, A. et al. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21, 952–965 (2001).
Park, J. et al. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 18, 3024–3033 (1999).
Stocker, H. et al. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295, 2088 –2091 (2002).Uses fly genetics to argue that Akt might be the sole effector of PIP 3 action.
Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99–102 (1999).
Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995).
Cheng, J. Q. et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93, 3636–3641 (1996).
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q. & Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81–86 (1998).
Philp, A. J. et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426–7429 (2001).
Jimenez, C. et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743–753 (1998).
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B. & Wong, A. J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 273, 200–206 (1998).
Watanabe, T. et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol. Oncol. 81, 172–177 (2001).
Barlund, M. et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60, 5340–5344 (2000).
Barlund, M. et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl Cancer Inst. 92, 1252–1259 (2000).
Ali, I. U., Schriml, L. M. & Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst. 91, 1922–1932 (1999).A thorough review of the frequency of PTEN mutation in various cancers.
Georgescu, M. M., Kirsch, K. H., Akagi, T., Shishido, T. & Hanafusa, H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl Acad. Sci. USA 96, 10182–10187 (1999).
Whang, Y. et al. Frequent transcriptional silencing of the tumor suppressor PTEN/MMAC1 gene in prostate cancer xenografts. Proc. Natl Acad. Sci. USA 95, 5246 (1998).
Pekarsky, Y. et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl Acad. Sci. USA 97, 3028–3033 (2000).
Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537–2548 (2000).Shows that cardiac-specific expression of constitutively active p110 causes an enlargement of the heart and that dominant-negative p110 causes a reduction in heart size.
Shioi, T. et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799–2809 (2002).
Borlado, L. R. et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14, 895–903 (2000).
Jones, R. G. et al. Protein kinase B regulates T lymphocyte survival, nuclear factor κB activation, and Bcl-xL levels in vivo. J. Exp. Med. 191, 1721–1734 (2000).
Tuttle, R. L. et al. Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα. Nature Med. 7, 1133–1137 (2001).
Bernal-Mizrachi, E., Wen, W., Stahlhut, S., Welling, C. M. & Permutt, M. A. Islet β-cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J. Clin. Invest. 108, 1631–1638 (2001).
Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R. & Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell. Biol. 21, 2203–2212 (2001).
Holland, E. C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genet. 25, 55–57 (2000).Shows that co-expression of activated Ras and Akt in neural progenitor cells in the mouse brain induces glioblastoma.
Stambolic, V. et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in Pten+/− mice. Cancer Res. 60, 3605–3611 (2000).
Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169–1178 (1998).
Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563–1568 (1999).
Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nature Genet. 19, 348–355 (1998).The first report of a Pten -knockout mouse phenotype. Homozygous deletion causes embryonic lethality, whereas heterozygous animals are viable but develop various tumors.
Goldman, J. M. & Melo, J. V. Targeting the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1084–1086 (2001).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
van Oosterom, A. T. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421–1423 (2001).
Baselga, J. et al. in 2001 AACR-NCI–EORTC International Conference 128 (American Association for Cancer Research, Fontainebleau Hilton Hotel. Miami Beach, Florida, 2001).
Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1092 (2002).Shows that non-toxic doses of LY294002 can increase the efficacy of the chemotherapeutic paclitaxel in an ovarian cancer xenograft model.
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963–10968 (1999).Describes the phenotype of the p110α-targeted deletion.
Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-Abl proto-oncogene. Cell 65, 1153–1163 (1991).
Reith, A. D. et al. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-Kit receptor. Genes Dev. 4, 390–400 (1990).
Soriano, P. The PDGFα receptor is required for neural crest cell development and for normal patterning of the somites. Development 124, 2691–2700 (1997).
Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001).Shows that loss of PTEN or stable expression of constitutively active AKT sensitizes tumours to inhibition of mTOR.
Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl Acad. Sci. USA 98, 10320–10325 (2001).Shows that pre-neoplastic uterine lesions fail to develop or regress in Pten+/− mice that are treated with an inhibitor of mTor.
Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med. 8, 128–135 (2002).
Chan, J. et al. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 1, 257–267 (2002).
Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. & Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484–5489 (2002).
Li, D. M. & Sun, H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl Acad. Sci. USA 95, 15406–15411 (1998).
Heymont, J. et al. TEP1, the yeast homolog of the human tumor suppressor gene PTEN/MMAC1/TEP1, is linked to the phosphatidylinositol pathway and plays a role in the developmental process of sporulation. Proc. Natl Acad. Sci. USA 97, 12672–12677 (2000).
Casamayor, A., Torrance, P. D., Kobayashi, T., Thorner, J. & Alessi, D. R. Functional counterparts of mammalian protein kinases PDK1 and SGK in budding yeast. Curr. Biol. 9, 186–197 (1999).
Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Di Como, C. J. & Heitman, J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13, 3271–3279 (1999).
Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. & Longo, V. D. Regulation of longevity and stress resistance by Sch9 in yeast. Science 292, 288–290 (2001).
Morris, J. Z., Tissenbaum, H. A. & Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382, 536–539 (1996).Shows that mutations in Age1 , the C. elegans Pi3k homologue, causes dauer formation and an extension of lifespan.
Kimura, K. D., Tissenbaum, H. A., Liu, Y. & Ruvkun, G. daf2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277, 942–946 (1997).
Paradis, S., Ailion, M., Toker, A., Thomas, J. H. & Ruvkun, G. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 13, 1438–1452 (1999).
Lin, K., Hsin, H., Libina, N. & Kenyon, C. Regulation of the Caenorhabditis elegans longevity protein DAF16 by insulin/IGF1 and germline signaling. Nature Genet. 28, 139–145 (2001).
Mihaylova, V. T., Borland, C. Z., Manjarrez, L., Stern, M. J. & Sun, H. The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Proc. Natl Acad. Sci. USA 96, 7427–7432 (1999).
Verdu, J., Buratovich, M. A., Wilder, E. L. & Birnbaum, M. J. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nature Cell Biol. 1, 500–506 (1999).
Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C. & Neufeld, T. P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14, 2712–2724 (2000).
Miron, M. et al. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nature Cell Biol. 3, 596–601 (2001).
Goberdhan, D. C., Paricio, N., Goodman, E. C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13, 3244–3258 (1999).Shows that in Drosophila , Pten is a negative regulator of Pi3k and mutations in Pten result in increased cell size and cell number.
Gao, X., Neufeld, T. P. & Pan, D. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and-independent pathways. Dev. Biol. 221, 404–418 (2000).
Sasaki, T. et al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ. Nature 406, 897–902 (2000).
Fruman, D. A. et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85α. Nature Genet. 26, 379–382 (2000).Shows that targeted deletion of all isoforms of Pi3k regulatory subunits results in lethality, unlike deletions of individual isoforms.
Suzuki, H. et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 283, 390–392 (1999).
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349–38352 (2001).
Chen, W. S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203–2208 (2001).Shows that Akt1 -deficient mice are smaller than wild-type littermates, have a shorter lifespan after exposure to genotoxic stress and show more susceptibility to apoptosis in the testes and thymus.
Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728–1731 (2001).
Wang, S. I. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183–4186 (1997).
Saito, M. et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int. J. Cancer 85, 160–165 (2000).
Sun, M. et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159, 431–437 (2001).
Teng, D. H. et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57, 5221–5225 (1997).
Sun, M. et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor-α (ERα) via interaction between ERα and PI3K. Cancer Res. 61, 5985–5991 (2001).
Yokoyama, Y. et al. Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int. J. Mol. Med. 6, 47–50 (2000).
Salvesen, H. B. et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22–26 (2001).
Kawamura, N. et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn. J. Cancer Res. 90, 413–418 (1999).
Celebi, J. T., Shendrik, I., Silvers, D. N. & Peacocke, M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 37, 653–657 (2000).
Zhou, X. P. et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157, 1123–1128 (2000).
Chang, J. G. et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur. J. Cancer 35, 647–651 (1999).
Forgacs, E. et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17, 1557–1565 (1998).
Alimov, A. et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 19, 3841–3846 (1999).
Dahia, P. L. et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 57, 4710–4713 (1997).
Halachmi, N. et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosom. Cancer 23, 239–243 (1998).
Hsieh, M. C. et al. Mutation analysis of PTEN/MMAC1 in sporadic thyroid tumors. Kaohsiung J. Med. Sci. 16, 9–12 (2000).
Ringel, M. D. et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 61, 6105–6111 (2001).
Nakahara, Y. et al. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 12, 1277–1280 (1998).
Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410–3415 (1998).
Fruman, D. A. et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283, 393–397 (1999).
Terauchi, Y. et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nature Genet. 21, 230–235 (1999).
Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase-γ in inflammation. Science 287, 1049–1053 (2000).
Li, Z. et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046–1049 (2000).